Home > Newsletters > FDAnews Drug Daily Bulletin > Teva’s Novel Oral Contraceptive Keeps Up With Competitors in Trial
FDAnews Drug Daily Bulletin
Nov. 12, 2012 | Vol. 9 No. 222
Teva’s Novel Oral Contraceptive Keeps Up With Competitors in Trial
Teva’s ascending-dose, extended-regimen oral contraceptive Quartette is effective at preventing pregnancy and has a comparable safety profile to other oral birth control pills, the company said. Quartette (levonorgestrel/ethinyl estradiol tablets and ethinyl estradiol tablets) was accepted for FDA review Aug. 13 and would be the first ascending-dose, extended-regimen birth control pill.
Washington Drug Letter
ePublishing :: CMS, Hosting & Web Development | © Copyright by FDAnewsAll rights reserved. Do not duplicate or redistribute in any form.